Quantbot Technologies LP Purchases Shares of 2,350 Axon Enterprise, Inc $AXON

Quantbot Technologies LP acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the third quarter, HoldingsChannel reports. The fund acquired 2,350 shares of the biotechnology company’s stock, valued at approximately $1,686,000.

A number of other institutional investors and hedge funds also recently modified their holdings of AXON. Brighton Jones LLC bought a new position in Axon Enterprise during the fourth quarter worth about $480,000. NewEdge Advisors LLC lifted its position in shares of Axon Enterprise by 41.1% in the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after buying an additional 668 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after acquiring an additional 157 shares during the period. Woodline Partners LP increased its holdings in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after acquiring an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Axon Enterprise in the 2nd quarter valued at $284,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: February quarter beat: Axon reported upside to EPS and revenue (strong ARR/subscription growth and bookings highlighted on the earnings call), reinforcing the company’s SaaS-like recurring revenue narrative and supporting future growth expectations. Earnings Call Highlights
• Positive Sentiment: Analyst bullishness: TD Cowen and other brokers have raised price targets and reiterated buy/outperform views after strong bookings and ARR trends (TD Cowen raised its target), giving institutional support to the bull case. Price Target Raised After Strong Bookings Growth
• Neutral Sentiment: Investor outreach/visibility: Management presented at the Morgan Stanley TMT conference — useful for investor engagement but the transcript did not contain new guidance or surprises that would immediately re-rate the stock. Conference Presentation Transcript
• Neutral Sentiment: Market commentary is mixed: post-earnings coverage praises growth (Axon 911, ARR) but flags a very rich forward multiple, meaning the stock needs continued execution to justify valuation. Zacks and other roundups mention Axon among featured ideas but do not change near-term fundamentals. Zacks Investment Ideas
• Negative Sentiment: Insider selling: Director/insider Isaiah Fields sold 2,000 shares (~$535 avg), trimming his stake — such sales can be perceived negatively and add pressure to sentiment. SEC Filing — Fields Sale
• Negative Sentiment: Additional insider sale: CAO Jennifer H. Mak sold 1,500 shares at roughly $573.45, further signaling insiders taking chips off the table. SEC Filing — Mak Sale
• Negative Sentiment: Aggregated coverage (TipRanks, MarketBeat) notes multiple insider sales in a short window, which can amplify investor concern about near-term selling pressure even if trades are modest. Insider Sales Coverage

Analysts Set New Price Targets

AXON has been the subject of a number of research analyst reports. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. UBS Group cut their price objective on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $569.81 on Thursday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $45.81 billion, a price-to-earnings ratio of 374.88, a price-to-earnings-growth ratio of 12.36 and a beta of 1.46. Axon Enterprise, Inc has a twelve month low of $396.41 and a twelve month high of $885.91. The company has a 50-day simple moving average of $536.69 and a two-hundred day simple moving average of $620.70.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the firm earned $2.08 earnings per share. Analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Activity

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, February 27th. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brittany Bagley sold 2,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the sale, the chief financial officer directly owned 103,501 shares in the company, valued at approximately $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 56,634 shares of company stock worth $31,534,295. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.